Adriatic sea

Trieste

giacca@icgeb.orghttp://www.icgeb.org

Mauro Giacca, MD PhDDirector, ICGEB Trieste, Italy

Biotecnologie per lo sviluppo internazionale

IL SISTEMA SCIENTIFICO FVG E LA COLLABORAZIONE TRA RICERCA, IMPRESA E GOVERNANCE PUBBLICA NELL’AMBITO DELLE BIOTECNOLOGIE

XIII Conferenza annuale del Coordinamento regionale degli Enti di Ricerca

AREA Science Park Padriciano 99 - Trieste Centro Congressi (Edificio C - Conference Hall )16 DICEMBRE 2014 - ORE 9.30

Le biotecnologie e le loro svariate applicazioni nei Centri di

ricerca del territorio, dall’ambito alimentare all’ingegneria

genetica, saranno il tema centrale della Conferenza annuale

degli Enti di Ricerca del Friuli Venezia Giulia.

Un incontro per presentare anche i recenti nuovi percorsi

di formazione sviluppati in condivisione con le aziende

leader nel settore, e per affrontare le nuove sfi de di Ricerca,

Innovazione e Trasferimento tecnologico.

Da sempre la crescita competitiva della regione è tra gli

obiettivi principali della Conferenza annuale degli Enti di

Ricerca del Friuli Venezia Giulia. Un traguardo raggiungibile

illustrando le esperienze già maturate, approfondendo le

possibili applicazioni, integrando i programmi di ricerca

e incrementando ulteriormente l’interazione tra i Centri di

ricerca nazionali e internazionali e le imprese.

Ministero dell ’ Istruzione,dell ’Università e della Ricerca

COME RAGGIUNGERE LA SEDEDELLA CONFERENZA

da Trieste cittàvia Fabio Severo - via A. Valerio -al bivio H girare a sinistrae ancora a sinistra e proseguire finoall’uscita Padriciano(indicazioni AREA in loco)

dall’autostrada A4uscita casello Lisert - proseguire fino all’uscita Padriciano (indicazioni AREA in loco)

martedì 16 dicembre, ore 9.30AREA Science Park Trieste, Padriciano 99Centro Congressi(Edificio C – Conference Hall)

SEGRETERIA ORGANIZZATIVA

Studio Sandrinelli srlRelazioni pubbliche e comunicazionevia Carducci 2234125 Triestetel. +39 040 362636eventi@studiosandrinelli.com

PROGRAMMA PROMEMORIA

Per ulteriori informazioni, il sito web di riferimento è: www.area.trieste.it/conferenzaCER_2014

SEGRETERIA SCIENTIFICA

Ginevra ToniniUfficio Coordinamento e Internazionalizzazionedegli Enti di Ricerca regionali

Servizio Formazione Progettazione e Gestione progetti

AREA Science Park34149 Padriciano, Triestetel. +39 040 3755263ginevra.tonini@area.trieste.it

Ministero degli Affari Esterie della Cooperazione Internazionale

9.30 RegistrazioneChair: Alfonso FranciosiPresidente Elettra-Sincrotrone Trieste S.C.p.A.

9.45 WelcomeAdriano De MaioPresidente AREA Science Park

10.00 Loredana PanaritiAssessore al lavoro, formazione, istruzione, pari opportunità, politiche giovanili e ricerca, Regione Autonoma Friuli Venezia Giulia

Il Network del Sistema Scientifico regionale: finalità, ruoli e nuove prospettive di collaborazione tra gli attori regionali della ricerca in Friuli Venezia Giulia

10.15 Diego BravarConfi ndustria Trieste

La collaborazione pubblico-privata per nuovi percorsi formativi: l’ITS Nuove Tecnologie della Vita

10.30 Alberto Felice De ToniRettore dell’Università degli Studi di Udine

Le biotecnologie per la qualità e la sicurezza nel campo alimentare

10.45 Maurizio FermegliaRettore dell’Università degli Studi di Trieste

Nano-bio-med: un’area strategica di sviluppo scientifico e tecnologico

11.00 Mauro GiaccaDirettore Generale ICGEB - International Centre for Genetic Engineering and Biotechnology

Biotecnologie per lo sviluppo internazionale

11.15 Guido MartinelliDirettore SISSA - Scuola Internazionale Superiore di Studi Avanzati

Ricerca in biologia molecolare, biotecnologie e l’impatto sul territorio e sull’impresa

11.30 Ugo FerreroDirezione Generale per la Promozione del Sistema Paese, Ministero degli Affari Esteri e della Cooperazione Internazionale

Il sistema scientifico e la promozione del Sistema Paese

11.45 Conclusioni a cura di Federico CinquepalmiDirezione Generale per l’Internazionalizzazione della Ricerca,Ministero dell’Istruzione, dell’Università e della Ricerca

Ebola Outbreak

The 2014 Ebola epidemic

Likely host = bats

1 in 2

How do you get the Ebola virus?

1 Body fluids of a person who is sick with or has died from Ebola.

2 Objects contaminated with the virus

3 Infected fruit bats or primates

Early Symptoms

FeverHeadacheFatigueDiarrheaVomiting

Stomach painUnexplained bleeding or bruisingMuscle pain

When is someone able to spreadthe disease to others?Ebola only spreadswhen people are sick.

After 21 days,MONTHS SFM T TW

541 326 12117 8 10913 191814 15 171620 262521 22 242327 28 29 3130

Virus di Ebola

Vaccini ricombinanti contro il virus di Ebola

Anticorpi monoclonali contro il virus di Ebola

Biopharmaceutical Products

InsulinHuman Growth Hormone (hGH)α-InterferonHepatitis B VaccineTissue Plasminogen Activator (TPA)Erythropoietin-αγ-InterferonGranulocyte Colony Stimulating Factor (G-CSF)Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)Interleukin 2Factor VIIIβ-InterferonDNase (Pulmozyme®)Glucocerebrosidase (Cerezyme®)ReoPro®

Source: Consulting Resources Corp.

Product

198219851986198619871989199019911991199219921993199319941994

Year

Humira (adalimumab) – Monoclonal antibody against TNFalpha

Enbrel (etanercept) – Fusion between the p75 TNFalpha receptor and an Ig

Remicade (infliximab) – Monoclonal antibody against TNFalpha

Seretide/Advair – Salmeterol and fluticasone

Lantus – insulin glargine

Rituxan (rituximab) – monoclonal antibody against B cell CD20

Avastin - monoclonal antibody against VEGF-A

Herceptin (trastuzumab) – monoclonal antibody against HER2/neu

Crestor (rosuvastatina) - statin

Abilifty (aripiprazolo) – schizophrenia and bipolar disorders

Late ‘70s and early ‘80s: Very successful biotech companies are born in the US (Genentech, 1976; Biogen, 1978; Amgen, 1980; Immunex, 1981; Chiron, 1981; Genzyme 1981)

early ‘80s: UNIDO functionaries in Vienna conceive the idea of a biotech Centre for developing countries

The early days in ICGEB history

1982: First meeting organized by UNIDO in Belgrade, Serbia

Late ‘70s and early ‘80s: Very successful biotech companies are born in the US (Genentech, 1976; Biogen, 1978; Amgen, 1980; Immunex, 1981; Chiron, 1981; Genzyme 1981)

early ‘80s: UNIDO functionaries in Vienna conceive the idea of a biotech Centre for developing countries

1982: First meeting organized by UNIDO in Belgrade, Serbia

1983: Foundation meeting in Madrid, Spain; Italy puts forward its candidature to host the Centre

1987: ICGEB is founded with two seats, one in Trieste, Italy and one in New Delhi, India

The early days in ICGEB history

To provide a Centre of excellence for research and

training in genetic engineering and

biotechnology addressed to developing countries and economies in transition

Developing knowledge

80+ Signatory States, 60+ Member States, 3 Components:Trieste (Italy) - New Delhi (India) - CapeTown (South Africa)

and a network of 40+ Affiliated Centres

Developing knowledge

CapeTown, South Africa

New Delhi, India

Trieste, Italy

ICGEB An intergovernmental organization in the United Nations Common System

• Cutting-edge scientific research in its laboratories in Trieste, New Delhi and Cape Town

• Advanced education supported by long- and short-term fellowships for PhD students and post-docs

• Organisation of Meetings, Courses and Workshops

• Competitive research grants for scientists in its Member Countries

• Technology transfer to industry for the production of biotherapeutics and diagnostics

The 5 instruments of action

ICGEB contents on iTunes USeminars and meeting presentations recorded in HD movie format and grouped in 28 different Collections

http://itunes.apple.com/us/institution/international-centre-for-genetic/id425107665

10/09/2011 - 03/05/2014

Tot. actions 347377

Browse Subscribe Download Stream Enclosure

170251 41931 81606 37551 16038

What's next?

80

How long shall we live?

60

40

20

Ancient Rome

22

Life

exp

ecta

ncy

(yea

rs)

1900

49

1970

70

2000

76

~1900 70 30

21

27

7

Life expectancy at birth in developed countries

Aging correlates with the sudden or progressive exhaustion of regenerative capacity in most organs and tissues after birth

Rubens, Philadelphia

Nicolas-Sebastien Adam, Paris, Louvre

"The hound of Zeus, the tawny eagle, ..... feasting on thy liver til he hath gnawn it black"

Aeschylys, Prometeus Bound

There is a pressing need to develop novel therapeutics for highly prevalent degenerative disorders

Ischemic cardiomyopathy and heart failure (HF)15 million HF patients worldwide; 50% of patients with HF die within 4 yearsNeurodegeneration30% of people over 80 years develop Alzheimer disease, and 1-3% of those over 65 years of age develop Parkinson's diseaseDiabetes mellitus>170 million people affected worldwide. Both Type 1 (autoimmune) and Type 2 (due to insulin resistance) diabetes are eventually determined by β-cell lossRetinal degenerationAge-related macular degeneration (AMD) is the leading cause of irreversible blindness, mostly affecting people over the age of 50. Prevalence of 30% in people over age 75 Presbycusis (Age-related hearing loss)Due to degeneration of hair cells of the cochlea and giant stereociliary cells. Affects >50% people over age 75

Biotherapeutics for degenerative conditions

Synthetic peptides or recombinant proteins

Gene TherapyProtein-coding cDNA, siRNA, miRNA, miRNA inhibitor. Which vector? Syringe containing factor,

vector or stem cells

Cell TherapyStem cell? Source?

Tissue protection Improved function

Regeneration

Cardiovascular disorders are the most common, serious, chronic, life-threatening disease causing more deaths, disability and economic costs than all other diseases, including cancer.

More than 1 person out of 3 dies because of cardiovascular disorders, including myocardial infarction (42%) or stroke (36%). The total deaths due to these diseases per year is >17 million people worldwide.

More than 50% of patients with ischemic cardiomyopathy develop towards heart failure; t

Causes of deathWorld Health Organization, 2011

Global Atlas on cardiovascular disease prevention and control, WHO 2011

The tremendous burden of cardiovascular disorders

giacca@icgeb.org